Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Kristy Grabowski - IR Aditya Mohanty - CEO & Director Eric d'Esparbes - EVP & CFO Conference Call Participants Yuan Zhi - B. Riley Securities Matthew Keller - H.C. Wainwright & Co. Operator Welcome to the Biora Therapeutics First Quarter 2023 Financial Results Call. [Operator Instructions]. I will now turn the call over to Kristy Grabowski, Director of IR Communications with LifeSci Advisors ...

7 Other Assets Other assets consisted of the following (in thousands): Prepaid expenses and other current assets consisted of the following (in thousands): Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Prepaid Expenses and Other Current Assets | --- | --- | --- | --- | --- | |--------------------------|-------|--------------------------|-------|-----------------------------| | Prepaid expenses | $ | March 31, 2023 \n3,059 | $ | December 31, 2022 \n3,634 | ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Chuck Padala – Managing Director-LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d'Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Sahil Kazmi – B. Riley Securities Operator Thank you for standing by. This is the conference operator. Welcome to the Biora Therapeutics Fourth Quarter 2022 Financial Results Conference Call. As a reminder, all ...

36 The initiation and completion of any clinical studies may be prevented, delayed, or halted for numerous reasons. We may experience delays in initiation or completion of our clinical trials for a number of reasons, which could adversely affect the costs, timing, or success of our clinical trials, including related to the following: • we may be required to submit an IDE application to the FDA with respect to our medical device product candidates, which must become effective prior to commencing certain huma ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2022 Results Conference Call November 14, 2022 4:30 PM ET Company Participants Alexandra Schuman - IR, LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Julian Harrison - BTIG Mayank Mamtani - B. Riley Securities Operator Welcome to the Biora Therapeutics Third Quarter 2022 Earnings Call. As a reminder, all participants are in listen-only mode and the conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39334 Biora Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3950390 (State or other jurisdiction ...

CORPORATE PRESENTATION August 2022 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fact included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, plans or intentions relating to product candidates, es ...

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Adi Mohanty – Chief Executive Officer Eric d’Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Yuan Zhi – B. Riley Operator Greetings and welcome to the Biora Therapeutics Second Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39334 Biora Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3950390 (State or other jurisdiction of i ...

CORPORATE PRESENTATION May 2022 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this presentation, including statements concerning our plans, objectives, goals, strategies, future events, plans or intentions relating to product candidates, esti ...